Anti-TNF-α therapies in chronic obstructive pulmonary diseases

Expert Opinion on Investigational Drugs

Volumn 17, Issue 8, 2008, Pages 1203-1211

  Antoniu, Sabina A ^a   Mihaltan, Florin ^b   Ulmeanu, Ruxandra ^c  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c National Institute of Pneumology M Nasta   (Romania)

Author keywords

Asthma; COPD; Etanercept; Infliximab; TNF

Indexed keywords

ADALIMUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 5; LENERCEPT; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADD ON THERAPY; AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BREAST CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; GENE EXPRESSION; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LUNG CANCER; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PROTEIN FUNCTION; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SEPSIS; SERUM SICKNESS; SIDE EFFECT; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; DRUG ANTAGONISM; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51449089674     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.8.1203     Document Type: Review

References (56)

1. GINA Report, Global Strategy for Asthma Management and Prevention; 2007 update. Available from: http://www.ginasthma.org/ Guidelineitem.asp?11=2&12intId=60 (last accessed March 2008)
2. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high close glucocorticoids. Am J Respir Crit Care Med 1997;156(3 Pt 1):737-43
3. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153(2):530-4
4. The GOLD Workshop Report (Updated 2007). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. In; 2007 update. Available from: http://www.goldcopd.com/ Guidelineitem.asp?11=2&12=1&intId=989. (last accessed March 2008)
5. Antoniu SA, Mlihaescu T, Donner CF. Inhaled therapy for stable chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;9(6):777-85
6. Kim J, Remick DG. Tumor necrosis factor inhibitors for the treatment of asthma. Curr Allergy Asthma Rep 2007;7(2):151-6,
7. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006;7:125
8. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of rumors. Proc Natl Acad Sci USA 1975;72(9):3666-70
9. Sheehan KC, Pinckard JK, Arthur CD, et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 1995;181(2):607-17.
10. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 2007;109(9):3640-8
11. Kim J, McKinley L, Natarajan S, et al. Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 2006;36(1):122-32
12. Amrani Y, Chen H, Panettieri RA Jr. Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma. Respir Res 2000;1(1):49-53
13. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991;88(4):561-71
14. Ohkawara Y, Lei XF, Stampfli MR, et al. Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 1997;16(5):510-20
15. Nakae S, Lunderius C, Ho LH, et al. TNF can contribute to multiple features of ovalbumin-induced allergic inflammation of the airways in mice. J Allergy Clin Immunol 2007;119(3):680-6
16. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002;57(9):774-8
17. Widegren HEJ, Korsgren M, Andersson M, Greiff L. Effects of intranasal TNF-alpha on granulocyte recruitment and activity in healthy subjects and patients with allergic rhinitis. Respir Res 2008;9:15
18. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60(12):1012-8
19. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354(7):697-708
20. Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of turnout necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflamation? Clin Exp Allergy 2006;36(11):1373-81
21. Hutchison S, Choo-Kang BS, Bundick RV, et al. Tumour necrosis factor-alpha blockade suppresses murine allergic airways inflammation. Clin Exp Immunol 2008;151(1):114-22
22. Di Francia. M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150(5 Pt 1):1453-5
23. De Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153(2):633-7
24. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptor are increased in sputum. Am J Respir Crit Care Med 2002;166(9):1218-24
25. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1179-84
26. Garrod R, Marshall J, Barley E, et al. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2007;16(4):236-40
27. Aoki T, Hirota T, Tamari M, et al. An association between asthma and TNF-308G/A polymorphism: meta-analysis. J Hum Genet 2006;51(8):677-85
28. Gao J, Shan G, Sun B, et al. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax 2006;61(6):466-71
29. Tanaka G, Sandford AJ, Burkett K, et al. Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. Eur Respir J 2007;29(1):34-41
30. Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000;118(4):971-5
31. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008;21(1):234-8
32. Nanda S, Bathon JM. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother 2004;5(5):1175-86
33. Mohler EM, Murray KM, Mann DL, Francis G. Use of targeted anticytokine treatments in heart failure. Circulation 2000;102(9):E65
34. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors ate effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151(3):1548-61
35. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004;5(3):581-94
36. EMEA. EnbrelEPAR for authorised medicinal products for human use EMEA; 2007. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/ enbrel/enbrel.htm (last accessed March 2008)
37. Toussirot E, Wendling D. The use of TNF-alpha blocking agents rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8(13):2089-107
38. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008;5:2
39. The Wegener's Granulomatosis Etanercept Trial Research G. Etanercept plus Standard Therapy for Wegener's Granulomatosis. N Engl J Med 2005;352(4):351-61
40. Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33(9):1802-4
41. Sanchez Carazo JL, Mahiques Santos I, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006;29(8):675-85
42. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005;44(6):714-20
43. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39(8):1254-55
44. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38(9):1261-5
45. Nie Z, Jacoby DB, Fryer AD. Etanercept prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. ATS International Conference 2007; Toronto; 2007
46. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble Tnf-A receptor fusion protein (etanercept) in corticosteroid-refractory asthma: a double blind, randomised placebo-controlled trial. Thorax 2008 [Epub ahead of print] doi:10.1136/thx.2007.086314
47. Rouhani FN, Meitin CA, Kaler M, et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005;99(9):1175-82
48. Diaz-Ley B, Guhl G, Fernandez-Herrera J. Off-label use of biologic agents in the treatment of dermatosis Part 1. Infliximab and adalimumab. Actas Dermosifiliogr 2007;98(10):657-78
49. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126(1):13-30
50. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174(7):795-802
51. Van Der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(4):465-9
52. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(9):926-34
53. Dentener MA, Creutzberg EC, Periings HJ, et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 2008 [Epub ahead of print] DOI: 10.1159/000117386
54. Erin EM, Leaker BR. Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006;174(7):753-62
55. Trifilieff A, Walker C, Keller T, et al. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br J Pharmacol 2002;135(7):1655-64
56. RemicadeEuropean Public Assessment Report. European Medicines Agency; 2008 revision. Available from: http://www.emea.europa.eu/humandocs/Humam/ EPAR/remicade/remicade.htm [last accessed March 2008]